Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH
- PMID: 33822348
- DOI: 10.1055/a-1469-7481
Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH
Erratum in
-
Erratum: Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.Hamostaseologie. 2021 Jun;41(3):e1. doi: 10.1055/s-0041-1729135. Epub 2021 May 12. Hamostaseologie. 2021. PMID: 33979842 No abstract available.
Abstract
The COVID-19 pandemic is an ongoing global healthcare crisis. Based on reports of atypically located thromboses following vaccination with the AstraZeneca COVID-19 vaccine, the Society of Thrombosis and Haemostasis Research (GTH) has issued guidance statements on the recognition, diagnosis, and treatment of this rare complication. It shares pathophysiological features with heparin-induced thrombocytopenia (HIT) and is referred to as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).
Die COVID-19 Pandemie stellt eine andauernde globale Gesundheitskrise dar. Basierend auf den Berichten über atypisch lokalisierte Thrombosen nach Impfung mit dem AstraZeneca COVID-19 Vakzin hat die Gesellschaft für Thrombose- und Hämostaseforschung (GTH) Handlungsempfehlungen zur Erkennung, Diagnostik und Therapie dieser seltenen Komplikation formuliert. Ihre Pathophysiologie ähnelt derjenigen der Heparin-induzierten Thrombozytopenie (HIT) und wird als Vakzin-induzierte prothrombotische Immunthrombozytopenie (VIPIT) bezeichnet.
Thieme. All rights reserved.
Conflict of interest statement
J.O. has received personal fees for lectures or consultancy and/or research support from Bayer, Biogen Idec, Biotest, Chugai, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, SOBI, and Takeda, outside the submitted work.R.K. reports grants and personal fees from Bayer, grants and personal fees from LEO Pharma, personal fees from Pfizer, personal fees from Bristol-Myers Squibb, and grants and personal fees from Daiichi Sankyo, outside the submitted work.F.L. has received personal fees for lectures, advisory boards, or consultancy and/or research support from Aspen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, LEO Pharma, Pfizer, and Sanofi, outside the submitted work.M.A. has served as a member of the Paediatric Expert Working Group for Boehringer Ingelheim and Daiichi Sankyo, outside the submitted work.C.A. has received personal fees for lectures and/or advisory boards from Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Pfizer, and Sanofi, outside the submitted work.W.K. has received personal fees, research grants, and/or travel support from AxonLab, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Portola, Sanofi, and SOBI, outside the submitted work.R.E.S. reports grants and personal fees from Bayer HealthCare, personal fees from Bayer Vital, personal fees from CSL Behring, grants and personal fees from Pfizer, and personal fees from Takeda, outside the submitted work.A.G. has received personal fees, grants, and/or travel support from Aspen, Bayer, Boehringer Ingelheim, Biokit, BioMarin/Prosensa, Blau Farmaceutica, Chromatec, DRK-BSD Baden-Württemberg/Hessen, DRK-BSD NSTOB, Ergomed, Gore Inc., Instrumentation Laboratory, Macopharma, ParinGenix, Portola, Roche, Rovi, Sagent, and Sanofi, outside the submitted work.C.v.A. and B.P. declare no conflicts of interest.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
